All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
FDA priority review for KymriahTM (tisagenlecleucel) in the treatment of adult R/R DLBCL
On 17th January 2018, Novartis announced in a press release that their CAR-T therapy KymriahTM (tisagencleucel) has been granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell Lymphoma (DLBCL) and who are ineligible for autologous stem cell transplant or have relapsed after transplant. This follows a Biologics License Application that was submitted to the FDA in November 2017.
Data from the JULIET study in adult R/R DLBCL helped to support the application for KymriahTM in this indication. Stephen Schuster, Director of Lymphoma at Penn Medicine, presented the primary analysis of the JULIET trial at the American Society of Hematology 2017, that demonstrated a complete response rate of 30% that was sustained up to 6 months in 95% of patients. Dr Schuster was interviewed by the Lymphoma Hub at the International Conference on Malignant Lymphoma (ICML) 2017 on the interim analysis of the JULIET trial. He described CAR-T therapy as a "transformation in the field of lymphoma therapeutics" and that it could "save many more lives than we have been able to in the past."
KymriahTM was the first CAR-T therapy approved in the US for the treatment of young patients up to the age of 25 diagnosed with R/R B-cell precursor acute lymphoblastic leukemia (ALL). A marketing authorization application was also submitted to the EMA in November 2017 for two indications; the treatment of children and young adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) and adult patients with R/R diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT).